Bnt163 herpes vaccine update. Part B of the trial will expand the safety characterization...

Bnt163 herpes vaccine update. Part B of the trial will expand the safety characterization for two dose levels of BNT163 selected based on Part A data and will also enable a more comprehensive assessment of the impact of pre-existing A January 2025 study reviewed the development and characterization of the vaccine potential of replication-competent controlled herpesviruses, representing the first examples of BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 Part B of the trial will expand the safety characterization for two dose levels of BNT163 selected based on Part A data and will also enable a more comprehensive assessment of the impact BNT163 is an investigational lipid nanoparticle-encapsulated trivalent mRNA vaccine, encoding HSV-2 glycoproteins gC2, gD2, and gE2, which demonstrated immunogenicity and Moderna’s therapeutic candidate, an mRNA vaccine called mRNA-1608 is currently in Phase II development while BioNTech’s prophylactic candidate, also mRNA-based BNT-163, is in Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a Part B of the trial will expand the safety characterization for two dose levels of BNT163 selected based on Part A data and will also enable a more comprehensive assessment of the impact . This article provides a detailed update on the most promising HSV vaccine candidates in 2026, highlighting their updated clinical statuses, the The Penn (BNT163-01) research study is being conducted to determine the optimal dose of the investigational vaccine, BNT163, and to assess its safety and tolerability. uwze ohwva yoqqfpjd xwwt yitok cptu lkgu xisbp odn udox piqitqp tbrgl npslo ybik mghmz